PerkinElmer

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. With a global network and localized agility, the company serves a diverse range of organizations from pharmaceutical and biotech to clinical labs, academia, and governments. It is headquartered in Waltham, MA.

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 41st Annual Cowen Health Care Conference on Monday, March 1, 2021 from 12:20 p.m. to 12:50 p.m. ET. Prahlad Singh, president and chief executive officer of PerkinElmer, will provide an update on the Company and its strategic priorities. A live audio webcast of the presentation will also be available on the Investors s

PerkinElmer to Present at Cowen Health Care Conference

NEW ORLEANS, Feb. 9, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Oxford Immunotec Global PLC (NasdaqGS: OXFD) to PerkinElmer, Inc. (NYSE: PKI). Under the...

OXFORD IMMUNOTEC INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oxford Immunotec Global PLC - OXFD

The short answer: Increased demand for COVID-19 testing.

How PerkinElmer Beat Expectations in Q4

PerkinElmer, Inc. (PKI) CEO Prahlad Singh on Q4 2020 Results - Earnings Call Transcript

PerkinElmer (PKI) delivered earnings and revenue surprises of 9.70% and 7.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

PerkinElmer (PKI) Surpasses Q4 Earnings and Revenue Estimates

Shares of PerkinElmer (NYSE:PKI) moved higher by 0.1% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 193.33% over the past year to $3.96, which beat the estimate of $3.00.

PerkinElmer: Q4 Earnings Insights

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 3, 2021. Fourth Quarter 2020 The Company reported GAAP earnings per share from continuing operations of $3.38, as compared to GAAP earnings per share from continuing operations of $0.58 in the fourth quarter of 2019. GAAP revenue for the quarter was $1.355 billion, as compared to $805 mi

PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020

PerkinElmer (NYSE:PKI) unveils its next round of earnings this Tuesday, February 02. Here is Benzinga's everything-that-matters guide for the earnings announcement.

PerkinElmer's Earnings: A Preview

Crown Hlds

KeyCorp

ONEOK

Rockwell Automation

Robust sales growth is the key to survival in today's fast changing and highly competitive operating backdrop. Let's check Crown Holdings (CCK), Rockwell Automation (ROK), PerkinElmer (PKI), KeyCorp (KEY) & ONEOK (OKE) as these might witness solid sales growth.

5 Attractive Sales Growth Stocks to Power Your Portfolio

America Movil SAB de CV

Hibbett Sports

Hologic

Top Ranked Growth Stocks to Buy for January 27th

PerkinElmer's (PKI) fourth-quarter results are likely to reflect strong performance at Diagnostics segment.

PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?

PerkinElmer is absolutely on fire as preliminary fourth quarter results reveal. PerkinElmer is not a one-trick pony. It has been a long-term value creator for investors.

PerkinElmer: Healthy Diagnosis

PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PerkinElmer (PKI) Reports Next Week: Wall Street Expects Earnings Growth

Graphic Packaging Hld

PulteGroup

Top Ranked Growth Stocks to Buy for January 21st

PerkinElmer (PKI) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why PerkinElmer (PKI) Is a Great Growth Stock

Bruker

Mettler-Toledo

Waters

4 Stocks to Watch on Rising Demand for Scientific Instruments

PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why PerkinElmer (PKI) Could Beat Earnings Estimates Again

Focus Financial Partners

Sally Beauty Hlds

Top Ranked Growth Stocks to Buy for January 20th

Amedisys

Allscripts Healthcare Solutions

Following are the three MedTech trends, which showed a steady momentum through the pandemic year and are likely to sustain even after the economic mayhem subsides.

3 Biggest MedTech Trends to Watch in 2021 for Better Returns

PerkinElmer's (PKI) RT-PCR assay to test individuals without COVID-19 symptoms acts as prime factor in controlling the spread.

PerkinElmer (PKI) Receives FDA EUA for Asymptomatic Testing

BJ`s Wholesale Club Holdings Inc

General Motors

Top Ranked Growth Stocks to Buy for January 14th

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to test individuals without symptoms or other reasons to suspect COVID-19 infection. According to a new model from The Journal of the American Medical Association's Open Network developed by researchers from the Centers for Disease Control and Prevention, close to

PerkinElmer SARS-CoV-2 RT-PCR Assay Receives FDA EUA for Asymptomatic Testing

PerkinElmer's (PKI) acquisition of Oxford Immunotec will expand its portfolio of advanced infectious disease testing solutions.

PerkinElmer (PKI) to Buy Oxford Immunotec for $591 million

Shares of PerkinElmer Inc. rose 1.2% toward record territory in premarket trading Monday, after the life sciences diagnostics company provided an upbeat fourth-quarter earnings outlook, citing better-than-expected demand for its COVID-19-related offerings. The company expects adjusted earnings per share of $3.60, above the FactSet consensus of $2.81.

PerkinElmer's stock jumps into record territory after upbeat earnings outlook

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of approximately 66% and 63%, respectively, GAAP earnings per share from continuing operations of at least $2.88, and adjusted earnings per share from continuing operations of at least $3.60 for the fourth quarter ended January 3, 2021. The ongoing strong performance was driven by better-than-expect

News for PerkinElmer Stock (PKI)